A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel 175 mg m(-2) intravenously over 3 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, E. F., Fokkema, E., Biesma, B., Groen, H. J., Snoek, W., Postmus, P. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151229/
https://www.ncbi.nlm.nih.gov/pubmed/9461009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151229/
https://www.ncbi.nlm.nih.gov/pubmed/9461009

Ejemplares similares